# 1. Financial Performance ## A. Key Figures * Sales: ₹144.1 Cr Q2 (+8.6%) · ₹281.9 Cr H1 (+9.3%) * EBITDA: ₹4,527.1 Cr Q2 (+14.9%) · ₹8,828.7 Cr H1 (+17%) * EBITDA Margin: 31.3% Q2 (vs. 29.6% Q2 FY25) · 31.2% H1 * Net Profit: ₹31,180 Cr Q2 (+2.6%) · ₹61,141 Cr H1 adj. (+4.1%) * **EPS:** ₹13 per share (Q2) * Effective Tax Rate: 24.7% Q2 (24.5% guided), expected to hover around 25% for FY26 * Forex Gain: ₹4,305 Mn Q2 (vs. ₹1,281 Mn prior year) ## B. Revenue Growth * **Resilient Top-Line Performance:** Sales growth remained positive in Q2 and H1, reflecting **pricing discipline and volume stability** amid a challenging operating environment. ## C. Profit Margins * **EBITDA Margin Recovery:** Margins improved sequentially in Q2 despite prior-year high base, driven by **operational efficiency and cost control**. * **Net Profit Growth in Line with Revenue:** Bottom-line expansion matched sales momentum, with **strong gross margin of 3% in Q2** signaling effective input cost management. ## D. Tax Rate Trends * **Tax Rate Normalization Underway:** ETR expected to stabilize at **~25% for FY26** due to expiry of regional incentives in Assam and Sikkim; prior low rates were inflated by carry-forward benefits. * **Non-Recurring Tax Item:** Q2 includes a **₹140 Cr one-time tax charge from merger adjustment**, which distorts the reported rate but is excluded from core trend analysis. ## E. Cash Flow Trends * **Cash Flow Pressure Despite Profit Stability:** Consolidated net cash generation declined YoY due to **working capital build-up, GxMDL settlement, and outflows from recent brand acquisitions**. * **Strong Forex Contribution:** FX gains more than quadrupled YoY, providing a **meaningful boost to other income** and partially offsetting cash outflows. --- # 2. Product & Therapy Performance ## A. Key Figures * Innovative Medicines Sales: **$313M** global (+16.4%) · U.S. sales surpassing generics for first time **B. S. sales surpassing generics** for first time * **Innovative Medicines Revenue Contribution:** **$250M–$260M** (70–80% of global innovative business) ## B. Innovative Medicines Performance * **C. S. Leadership Shift:** Innovative Medicines now outpace generics in the U.S., signaling strategic success in premium product adoption. * **Ex-U.S. Momentum:** International innovative business shows strong double-digit growth, supported by ILUMYA’s expansion into **35 markets**, including recent launches driving commercial traction. * **Product-Specific Trends:** Lenalidomide stabilizes QoQ after YoY decline; Cequa maintains strong growth despite Restasis generics due to **differentiated patient support programs**. ## C. Generics Business Dynamics * **Revlimid Wind-Down:** Generic Revlimid revenue declined sequentially and is no longer a meaningful contributor, with only minimal sales expected for remainder of FY26. * **Dual-Strategy Continuity:** Despite U.S. generics headwinds, company remains committed to growing both generics and innovative portfolios. * **GLP-1 Pipeline Intent:** Plans to launch **pen-based semaglutide** in India; evaluating both oral and injectable forms to capture emerging generics opportunity. ## D. Key Product Uptake & Launch Execution * **ILUMYA Growth Runway:** Prescription momentum in psoriasis expected to continue, fueled by market expansion, clinical data, and enhanced promotional efforts. * **Leqselvi Commercial Traction:** Already generating paid prescription revenue with growth outlook sustained by rising JAK inhibitor adoption and low market penetration. * **Targeted Launch Support:** Leqselvi and Unloxcyt backed by dedicated sales force, underscoring focus on specialty dermatology and niche oncology segments. --- # 3. Geography & Market Mix ## A. Key Figures * **U.S. Revenue:** **$496 million** (–4.1%) **B. S. Revenue:** **$496 million** (–1%) * **Emerging Markets Revenue:** **$325 million** (+9% YoY, +8% CC) * **Rest of World Revenue:** **$234 million** (+7% YoY, +17–18% CC) * **India Sales:** **₹480 crore** (+11% YoY) ## B. U.S. Business Mix * **Strategic Shift:** U.S. business marks structural transition with **innovative products now surpassing generics** in revenue contribution, signaling successful portfolio transformation. * **Growth Drivers:** Revenue decline offset by strong performance in Innovative Medicines; **LEQSELVI shows positive early adoption** with expectations of expanding access. * **Pipeline Execution:** Three new generics launched alongside LEQSELVI, reinforcing commercial execution and diversification beyond traditional generics. ## C. Emerging Markets Growth * **Broad-Based Expansion:** Double-digit constant currency growth driven by balanced performance across Generics and Innovative Medicines, with **strong contributions from South Africa and Brazil**. * **Currency Tailwinds:** Favorable forex movements amplified reported growth, though underlying demand remains robust across key markets. ## D. Rest of World Sales * **Outperformance in Specialty:** ROW achieved **17–18% constant currency growth**, driven organically by ILUMYA and ODOMZO, with no one-off sales, highlighting sustainable momentum in non-U.S. specialty. * **Market Leadership:** **ODOMZO holds >60% share in European basal cell carcinoma market** and >50% among U.S. dermatologists, underpinning brand strength in niche dermatology. ## E. India Market Share * **Outperformance vs. Market:** India business grew significantly faster than IPM, driven by **volume gains and new product launches**, contrasting with price-led industry trends. * **Market Leadership:** Sun Pharma is **#1 brand by prescription volume** and leads across 13 doctor segments, despite a repositioned **3% overall market share** in a large and growing market. --- # 4. R&D & Pipeline Progress ## A. Key Figures * R&D Spend: **₹7,827 Mn** (5.4% of sales) · Innovative R&D: **38%** of total spend (~10% of Global Innovative Medicine sales) ## B. R&D Strategy & Development * **Innovation Focus:** Nearly two-fifths of R&D investment directed toward innovative programs, reflecting strategic prioritization of high-potential assets. * **Manufacturing Flexibility:** Development of **GL0034** currently uses synthetic route, with active evaluation of recombinant production for future scalability. ## C. Clinical Progress * **GL0034 Momentum:** Promising early data in MASH and diabetes; global Phase II trial initiation imminent, with data readout expected shortly. * **Utreglutide in Focus:** Phase II trials ongoing for type 2 diabetes, with no expansion into additional indications confirmed at this stage. ## D. Regulatory & Commercial Readiness * **E. S. Launch on Track:** UNLOXCYT launch expected in H2 FY26 pending FDA labeling decision; sBLA filing for ILUMYA in psoriatic arthritis planned concurrently. * **Global Filings Advancing:** Cosibelimab submission underway in Europe; semaglutide filing active in Canada, though commercialization timeline remains undisclosed. ## E. Study Data Timing * **Data Readouts Pending:** Phase II/III results for Fibromun in soft tissue sarcoma and glioblastoma not yet disclosed; Philogen-managed studies progressing without recruitment delays. --- # 5. Capital & Acquisition Activity ## A. Key Figures * Net Cash: $2.9 billion consolidated (post-acquisition & litigation settlement) * **Intangible Assets:** **> $950 Mn** (up from March '25, driven by Checkpoint and Leqselvi) * **Acquisition Consideration:** **$355 Mn** for Checkpoint (vs. INR 3,400 Cr investment in subsidiaries) * **Launch Investment:** **$100 Mn** allocated for Leqselvi and Unloxcyt launches in FY26 ## B. Acquisition Impact * **Strategic Capital Deployment:** Net cash position preserved at $9 billion despite major outflows for the Checkpoint acquisition and GxMDL settlement, reflecting disciplined capital management. * **Intangible Asset Growth:** Significant increase in intangibles driven by **Checkpoint's $471 Mn** valuation and **Leqselvi's $300 Mn** reclassification, with minor contributions from milestone payments including ODOMZO. * **Temporary Leverage Spike:** Short-term borrowings and associated interest costs rose temporarily to finance an acquisition, with management guiding for a return to prior-year debt levels in coming quarters. ## C. Launch Funding * **Commercial Readiness:** Full sales forces are in place for Leqselvi and Unloxcyt, with $100 million launch budget funding upfront fixed costs; spending ramping through H2 FY26. * **Sustainable Launch Model:** Upfront marketing expenses are largely one-time, with post-launch costs expected to stabilize around **sales force, marketing, and patient support programs** in FY27 and beyond. --- # 6. Pricing & Demand Risks ## A. Generic Competition * **Headline:** Restasis generics expected to erode Restasis share, with minimal spillover risk to Cequa or other brands in the category. ## B. Tariff Uncertainty * **Headline:** No near-term tariff risk for Innovative Medicines, as manufacturing is in U.S. trade agreement regions and proposed 100% tariffs remain on hold. * **Headline:** Company maintains operational flexibility, with existing **C. S. manufacturing footprint** and readiness to adapt supply chains amid unresolved Section 232 and Section 301 investigations. * **Headline:** Generics likely shielded from tariff impacts; branded drug exposure remains unclear, with no current assessment on ILUMYA or other IM products. ## C. Market Access * **Headline:** Cequa pricing impact from Restasis competition not addressed directly, reflecting strategic caution or lack of immediate pricing linkage. * **Headline:** U.S. and European biosimilar strategy pending **FDA guidance on substitution rules**, delaying firm commitments despite sector-wide investment momentum. --- # 7. Guidance & Outlook ## A. Key Figures * **R&D Spend:** **~5%** of sales (lower end of 6–8% guidance) * **Cash Flow:** Expected to **normalize by FY-end**, aligning with PBT growth ## B. R&D Strategy * **Disciplined R&D Outlook:** Spending to come in below guidance at approximately **5% of sales**, reflecting targeted investment amid pipeline development. ## C. Cash Flow Recovery * **Cash Flow Rebound Expected:** Decline is temporary, with recovery anticipated as working capital pressures and one-time outflows subside by year-end. ## D. Launch Timelines * **India GLP-1 Launch on Track:** Semaglutide set for first-wave launch post-patent expiry in **March 2026**, with product readiness confirmed. * **Strategic GLP-1 Participation:** Company to enter high-growth GLP-1 market at first opportunity, though no formal size or spend guidance provided. * **Canada Launch Status Unclear:** No update on semaglutide plans for Canada; regulatory or timing clarity remains pending.